COAPT试验:心衰合并继发性二尖瓣反流患者经导管二尖瓣修复后的健康状况
COAPT试验随机将症状性心衰合并3+至4+继发性二尖瓣反流患者分配至经导管二尖瓣修复(TMVr)组(n=302)或标准药物治疗组(n=312),旨在评估健康状况结局。结果显示,TMVr组在1个月时KCCQ总体评分较标准治疗组显著改善(组间差异15.9分,95%CI 12.3-19.5),且该获益持续至24个月(差异12.8分,95%CI 7.5-18.2)。
要点
- TMVr组1个月KCCQ-OS即显著改善,24个月时获益仍持续。
- 24个月时TMVr组36.4%患者存活且KCCQ改善≥10分,标准治疗组为16.6%。
- 需治疗人数(NNT)为5.1例(95%CI 3.6-8.7)以获得1例≥10分改善。
核心结论
- 在症状性心衰合并3+至4+继发性二尖瓣反流且已接受最大耐受药物治疗的患者中,缘对缘TMVr与单纯药物治疗相比,可带来显著且持续的早期健康状况改善。
研究设计与样本
- COAPT试验为随机对照试验,纳入症状性心衰合并3+至4+继发性二尖瓣反流患者,随机分配至TMVr组(n=302)或标准治疗组(n=312)。
- 健康状况采用堪萨斯城心肌病问卷(KCCQ)和SF-36健康调查在基线及1、6、12、24个月进行评估。
- 主要健康状态终点为KCCQ总体总结评分(KCCQ-OS,范围0-100,分数越高越好,最小临床重要差异为5分)。
主要发现
- 基线时患者健康状况明显受损(平均KCCQ-OS 52.4 ± 23.0)。
- 标准治疗组健康状况随时间未见变化,而TMVr组在1个月时KCCQ-OS显著改善(组间平均差异15.9分;95%CI 12.3至19.5分),至24个月时获益仅轻微减弱(平均差异12.8分;95%CI 7.5至18.2分)。
- 24个月时,TMVr组36.4%的患者存活且KCCQ-OS改善≥10分,标准治疗组为16.6%(p < 0.001),需治疗人数为5.1例(95%CI 3.6至8.7例)。
- TMVr组在各时间点SF-36总结评分也优于标准治疗组(24个月时生理维度平均差异3.6分;95%CI 1.4至5.8分;心理维度平均差异3.6分;95%CI 0.8至6.4分)。
临床怎么用
- 对于症状性心衰合并3+至4+继发性二尖瓣反流且已接受最大耐受药物治疗的患者,TMVr可显著改善健康状态,且获益早现并可持续至24个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) trial, transcatheter mitral valve repair (TMVr) led to reduced heart failure (HF) hospitalizations and improved survival in patients with symptomatic HF and 3+ to 4+ secondary mitral regurgitation (MR) on maximally-tolerated medical therapy. Given the advanced age and comorbidities of these patients, improvement in health status is also an important treatment goal. OBJECTIVES: The purpose of this study was to understand the health status outcomes of patients with HF and 3+ to 4+ secondary MR treated with TMVr versus standard care. METHODS: The COAPT trial randomized patients with HF and 3+ to 4+ secondary MR to TMVr (n = 302) or standard care (n = 312). Health status was assessed at baseline and at 1, 6, 12, and 24 months with the Kansas City Cardiomyopathy Questionnaire (KCCQ) and the SF-36 health status survey. The primary health status endpoint was the KCCQ overall summary score (KCCQ-OS; range 0 to 100; higher = better; minimum clinically important difference = 5 points). RESULTS: At baseline, patients had substantially impaired health status (mean KCCQ-OS 52.4 ± 23.0). While health status was unchanged over time in the standard care arm, patients randomized to TMVr demonstrated substantial improvement in the KCCQ-OS at 1 month (mean between-group difference 15.9 points; 95% confidence interval [CI]: 12.3 to 19.5 points), with only slight attenuation of this benefit through 24 months (mean between-group difference 12.8 points; 95% CI: 7.5 to 18.2 points). At 24 months, 36.4% of TMVr patients were alive with a moderately large (≥10-point) improvement versus 16.6% of standard care patients (p < 0.001), for a number needed to treat of 5.1 patients (95% CI: 3.6 to 8.7 patients). TMVr patients also reported better generic health status at each timepoint (24-month mean difference in SF-36 summary scores: physical 3.6 points; 95% CI: 1.4 to 5.8 points; mental 3.6 points; 95% CI: 0.8 to 6.4 points). CONCLUSIONS: Among patients with symptomatic HF and 3+ to 4+ secondary MR receiving maximally-tolerated medical therapy, edge-to-edge TMVr resulted in substantial early and sustained health status improvement compared with medical therapy alone. (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation [The COAPT Trial] [COAPT]; NCT01626079).
引用
- Arnold SV, Chinnakondepalli KM, Spertus JA, et al. Health Status After Transcatheter Mitral-Valve Repair in Heart Failure and Secondary Mitral Regurgitation: COAPT Trial. J Am Coll Cardiol. 2019. PMID: 30894288. doi:10.1016/j.jacc.2019.02.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。